Avalon GloboCare Corp. (NASDAQ:ALBT) Sees Large Growth in Short Interest

Avalon GloboCare Corp. (NASDAQ:ALBT) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 80,987 shares, a growth of 41.2% from the November 30th total of 57,363 shares. Based on an average trading volume of 193,362 shares, the days-to-cover ratio is presently 0.4 days. Currently, 2.1% of the company’s shares are sold short. Currently, 2.1% of the company’s shares are sold short. Based on an average trading volume of 193,362 shares, the days-to-cover ratio is presently 0.4 days.

Avalon GloboCare Stock Up 5.6%

Avalon GloboCare stock opened at $1.33 on Monday. The company has a 50 day moving average of $1.65 and a 200-day moving average of $2.18. Avalon GloboCare has a twelve month low of $0.88 and a twelve month high of $11.66. The stock has a market capitalization of $5.65 million, a PE ratio of -0.38 and a beta of -0.11.

Avalon GloboCare (NASDAQ:ALBT) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.06) earnings per share for the quarter. The firm had revenue of $0.35 million for the quarter.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Avalon GloboCare in a report on Wednesday, October 8th. Wall Street Zen cut shares of Avalon GloboCare to a “strong sell” rating in a research report on Saturday, September 13th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Avalon GloboCare

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.